There was no recurrence after 16 weeks of follow-up.
A 9-year-old girl revealed extensive erythematous plaques with coarse scales covering more than 80% of her body. Photo: Case Report / Wiley Pediatric Dermatology.
a patient The Puerto Rican pediatric patient surprised doctors with manifestations caused by severe plaque psoriasis that was refractory to many topical and systemic treatments.
The 9-year-old girl revealed extensive erythematous plaques with coarse scales covering more than 80% of her body surface, including her face, scalp, trunk and extremities.
Doctors at the Medical Sciences Complex decided to treat her with etanercept, the only FDA-approved biological option for this type of psoriasis, but after 9 months, her clinical response was minimal.
However, the team decided to start again. this patient Ustekinumab therapy following guidelines for adults weighing less than 100 kg.
Three weeks after the start of treatment, her psoriatic lesions had almost completely disappeared. There were no recurrences after 16 weeks of follow-up, no abnormalities in her laboratory results, and no major complications except one urinary tract infection Complex that resolved with oral antibiotics.
It should be noted that the use of ustekinumab is part of the study. “A phase 3 multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of this Treatment in Adolescents with Psoriasis moderate to severe plaque”, and fine data support the researchers’ proposal to validate it as a safe and effective biologic therapy for children aged 12-17 years.
However, the patient treated in Puerto Rico is 9 years old, and to date no studies have been conducted to evaluate the effectiveness of the treatment. Medication in young pediatric patients 12 years old, although this case may show that patients of this age may have healing potential.
Access the case here.